KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) EPS (Basic) (2018 - 2025)

Amneal Pharmaceuticals has reported EPS (Basic) over the past 8 years, most recently at $0.11 for Q4 2025.

  • Quarterly results put EPS (Basic) at $0.11 for Q4 2025, up 210.0% from a year ago — trailing twelve months through Dec 2025 was $0.23 (up 160.53% YoY), and the annual figure for FY2025 was $0.23, up 160.53%.
  • EPS (Basic) for Q4 2025 was $0.11 at Amneal Pharmaceuticals, up from $0.01 in the prior quarter.
  • Over the last five years, EPS (Basic) for AMRX hit a ceiling of $0.11 in Q4 2025 and a floor of -$0.8 in Q2 2022.
  • Median EPS (Basic) over the past 5 years was $0.0 (2022), compared with a mean of -$0.07.
  • Peak annual rise in EPS (Basic) hit 400.0% in 2023, while the deepest fall reached 1833.33% in 2023.
  • Amneal Pharmaceuticals' EPS (Basic) stood at -$0.04 in 2021, then increased by 25.0% to -$0.03 in 2022, then plummeted by 1833.33% to -$0.58 in 2023, then skyrocketed by 82.76% to -$0.1 in 2024, then soared by 210.0% to $0.11 in 2025.
  • The last three reported values for EPS (Basic) were $0.11 (Q4 2025), $0.01 (Q3 2025), and $0.07 (Q2 2025) per Business Quant data.